{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:39:13Z","timestamp":1794703153415,"version":"4.9.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Marsden Fund (Royal Society of New Zealand) (grant number UOO1807) Maurice Wilkins Centre for Molecular Biodiscovery","id":[{"id":"https:\/\/ror.org\/04tajb587","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The increasing incidence of drug resistance in\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    has diminished the efficacy of almost all available antibiotics, complicating efforts to combat the spread of this global health burden. Alongside the development of new drugs, optimised drug combinations are needed to improve treatment success and prevent the further spread of antibiotic resistance. Typically, antibiotic resistance leads to reduced sensitivity, yet in some cases the evolution of drug resistance can lead to enhanced sensitivity to unrelated drugs. This phenomenon of collateral sensitivity is largely unexplored in\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    but has the potential to identify alternative therapeutic strategies to combat drug-resistant strains that are unresponsive to current treatments. Here, by using drug susceptibility profiling, genomics and evolutionary studies we provide evidence for the existence of collateral drug sensitivities in an isogenic collection\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    drug-resistant strains. Furthermore, in proof-of-concept studies, we demonstrate how collateral drug phenotypes can be exploited to select against and prevent the emergence of drug-resistant strains. This study highlights that the evolution of drug resistance in\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    leads to collateral drug responses that can be exploited to design improved drug regimens.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-37184-7","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T16:01:56Z","timestamp":1679846516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3657-6995","authenticated-orcid":false,"given":"Natalie J. E.","family":"Waller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yi","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8349-1500","authenticated-orcid":false,"given":"Gregory M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,18]]},"reference":[{"key":"37184_CR1","unstructured":"World Health Organisation. Global Tuberculosis Report 2022 (WHO, 2022)."},{"key":"37184_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/antibiotics3030317","volume":"3","author":"JC Palomino","year":"2014","unstructured":"Palomino, J. C. & Martin, A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics 3, 317\u2013340 (2014).","journal-title":"Antibiotics"},{"key":"37184_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-98862-4","volume":"11","author":"PJ G\u00f3mez-Gonz\u00e1lez","year":"2021","unstructured":"G\u00f3mez-Gonz\u00e1lez, P. J. et al. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. Sci. Rep. 11, 1\u201313 (2021).","journal-title":"Sci. Rep."},{"key":"37184_CR4","doi-asserted-by":"publisher","first-page":"e02530","DOI":"10.1128\/AAC.02530-18","volume":"63","author":"H Ghajavand","year":"2019","unstructured":"Ghajavand, H. et al. High prevalence of bedaquiline resistance in treatment-naive tuberculosis patients and verapamil effectiveness. Antimicrob. Agents Chemother. 63, e02530\u201302518 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"37184_CR5","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.7b00217","author":"L Saxby Ross","year":"2018","unstructured":"Saxby Ross, L. et al. Identification of collateral sensitivity to dihydroorotate dehydrogenase inhibitors in Plasmodium falciparum. Infect. Dis. https:\/\/doi.org\/10.1021\/acsinfecdis.7b00217 (2018).","journal-title":"Infect. Dis."},{"key":"37184_CR6","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41564-018-0164-0","volume":"3","author":"V Lazar","year":"2018","unstructured":"Lazar, V. et al. Antibiotic-resistant bacteria show widespread collateral sensitivity to antimicrobial peptides. Nat. Microbiol. 3, 718\u2013731 (2018).","journal-title":"Nat. Microbiol."},{"key":"37184_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11684-018-0647-7","volume":"12","author":"L Wang","year":"2018","unstructured":"Wang, L. & Bernards, R. Taking advantage of drug resistance, a new approach in the war on cancer. Front. Med. 12, 490\u2013495 (2018).","journal-title":"Front. Med."},{"key":"37184_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06143-y","volume":"9","author":"NL Podnecky","year":"2018","unstructured":"Podnecky, N. L. et al. Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli. Nat. Commun. 9, 3673 (2018).","journal-title":"Nat. Commun."},{"key":"37184_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cell.2016.01.045","volume":"165","author":"B Zhao","year":"2016","unstructured":"Zhao, B. et al. Exploiting temporal collateral sensitivity in tumor clonal evolution. Cell 165, 234\u2013246 (2016).","journal-title":"Cell"},{"key":"37184_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.tim.2015.02.009","volume":"23","author":"C P\u00e1l","year":"2015","unstructured":"P\u00e1l, C., Papp, B. & L\u00e1z\u00e1r, V. Collateral sensitivity of antibiotic-resistant microbes. Trends Microbiol. 23, 401\u2013407 (2015).","journal-title":"Trends Microbiol."},{"key":"37184_CR11","doi-asserted-by":"publisher","first-page":"262ra156","DOI":"10.1126\/scitranslmed.3009940","volume":"6","author":"C Munck","year":"2014","unstructured":"Munck, C., Gumpert, H. K., Wallin, A. I., Wang, H. H. & Sommer, M. O. Prediction of resistance development against drug combinations by collateral responses to component drugs. Sci. Transl. Med. 6, 262ra156 (2014).","journal-title":"Sci. Transl. Med."},{"key":"37184_CR12","doi-asserted-by":"publisher","first-page":"204ra132","DOI":"10.1126\/scitranslmed.3006609","volume":"5","author":"L Imamovic","year":"2013","unstructured":"Imamovic, L. & Sommer, M. O. A. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci. Transl. Med. 5, 204ra132 (2013).","journal-title":"Sci. Transl. Med."},{"key":"37184_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08098-6","volume":"10","author":"D Nichol","year":"2019","unstructured":"Nichol, D. et al. Antibiotic collateral sensitivity is contingent on the repeatability of evolution. Nat. Commun. 10, 334 (2019).","journal-title":"Nat. Commun."},{"key":"37184_CR14","doi-asserted-by":"publisher","first-page":"e2121768119","DOI":"10.1073\/pnas.2121768119","volume":"119","author":"A Liakopoulos","year":"2022","unstructured":"Liakopoulos, A. et al. Allele-specific collateral and fitness effects determine the dynamics of fluoroquinolone resistance evolution. Proc. Natl Acad. Sci. USA 119, e2121768119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37184_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08529-y","volume":"10","author":"CEH Rosenkilde","year":"2019","unstructured":"Rosenkilde, C. E. H. et al. Collateral sensitivity constrains resistance evolution of the CTX-M-15 beta-lactamase. Nat. Commun. 10, 618 (2019).","journal-title":"Nat. Commun."},{"key":"37184_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ebiom.2016.05.041","volume":"9","author":"KA Cohen","year":"2016","unstructured":"Cohen, K. A. et al. Paradoxical hypersusceptibility of drug-resistant Mycobacterium tuberculosis to beta-lactam antibiotics. Ebiomedicine 9, 170\u2013179 (2016).","journal-title":"Ebiomedicine"},{"key":"37184_CR17","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1128\/AAC.00037-14","volume":"58","author":"RC Hartkoorn","year":"2014","unstructured":"Hartkoorn, R. C., Uplekar, S. & Cole, S. T. Cross-resistance between clofazimine and bedaquiline through upregulation of mmpl5 in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58, 2979\u20132981 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"37184_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.20420","volume":"6","author":"JE Gomez","year":"2017","unstructured":"Gomez, J. E. et al. Ribosomal mutations promote the evolution of antibiotic resistance in a multidrug environment. eLife 6, 1\u201325 (2017).","journal-title":"eLife"},{"key":"37184_CR19","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.3389\/fmicb.2019.01922","volume":"10","author":"JM Mouton","year":"2019","unstructured":"Mouton, J. M. et al. Comprehensive characterization of the attenuated double auxotroph Mycobacterium tuberculosis \u2206leuCD\u2206panCD as an alternative to H37Rv. Front. Microbiol. 10, 1922 (2019).","journal-title":"Front. Microbiol."},{"key":"37184_CR20","doi-asserted-by":"publisher","unstructured":"Vilch\u00e8ze, C. et al. Rational design of biosafety level 2-approved, multidrug-resistant strains of Mycobacterium tuberculosis through nutrient auxotrophy. MBio https:\/\/doi.org\/10.1128\/mBio.00938-18 (2018).","DOI":"10.1128\/mBio.00938-18"},{"key":"37184_CR21","doi-asserted-by":"publisher","first-page":"e01245-14","DOI":"10.1128\/mBio.01245-14","volume":"5","author":"P Jain","year":"2014","unstructured":"Jain, P. et al. Specialized transduction designed for precise high-throughput unmarked deletions in Mycobacterium tuberculosis. MBio 5, e01245-14 (2014).","journal-title":"MBio"},{"key":"37184_CR22","unstructured":"World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. https:\/\/www.who.int\/publications\/i\/item\/9789240028173 (2021)."},{"key":"37184_CR23","doi-asserted-by":"publisher","first-page":"e0119628","DOI":"10.1371\/journal.pone.0119628","volume":"10","author":"M Seifert","year":"2015","unstructured":"Seifert, M., Catanzaro, D., Catanzaro, A. & Rodwell, T. C. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS ONE 10, e0119628 (2015).","journal-title":"PLoS ONE"},{"key":"37184_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/jac\/dkp237","volume":"64","author":"IL Bergval","year":"2009","unstructured":"Bergval, I. L., Schuitema, A. R., Klatser, P. R. & Anthony, R. M. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J. Antimicrob. Chemother. 64, 515\u2013523 (2009).","journal-title":"J. Antimicrob. Chemother."},{"key":"37184_CR25","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/j.1365-2958.2008.06365.x","volume":"69","author":"C Vilch\u00e8ze","year":"2008","unstructured":"Vilch\u00e8ze, C. et al. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol. Microbiol. 69, 1316\u20131329 (2008).","journal-title":"Mol. Microbiol."},{"key":"37184_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1021\/acsinfecdis.8b00225","volume":"5","author":"X Lu","year":"2019","unstructured":"Lu, X. et al. Pyrazolo[1,5- a]pyridine inhibitor of the respiratory cytochrome bcc complex for the treatment of drug-resistant tuberculosis. ACS Infect. Dis. 5, 239\u2013249 (2019).","journal-title":"ACS Infect. Dis."},{"key":"37184_CR27","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/nm.3262","volume":"19","author":"K Pethe","year":"2013","unstructured":"Pethe, K. et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19, 1157\u20131160 (2013).","journal-title":"Nat. Med."},{"key":"37184_CR28","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/jac\/dki319","volume":"56","author":"M Protopopova","year":"2005","unstructured":"Protopopova, M. et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1, 2-ethylenediamines. J. Antimicrob. Chemother. 56, 968\u2013974 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"37184_CR29","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1021\/acsomega.0c05589","volume":"6","author":"PC Ray","year":"2021","unstructured":"Ray, P. C. et al. Spirocycle MmpL3 inhibitors with improved hERG and cytotoxicity profiles as inhibitors of Mycobacterium tuberculosis growth. ACS Omega 6, 2284\u20132311 (2021).","journal-title":"ACS Omega"},{"key":"37184_CR30","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1128\/AAC.05708-11","volume":"56","author":"K Tahlan","year":"2012","unstructured":"Tahlan, K. et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 1797\u20131809 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"37184_CR31","doi-asserted-by":"publisher","first-page":"636.e3","DOI":"10.1016\/j.cell.2019.01.003","volume":"176","author":"B Zhang","year":"2019","unstructured":"Zhang, B. et al. Crystal structures of membrane transporter MmpL3, an anti-TB drug target. Cell 176, 636.e3\u2013648.e3 (2019).","journal-title":"Cell"},{"key":"37184_CR32","doi-asserted-by":"crossref","unstructured":"McNeil, M. B., Dennison, D. & Parish, T. Mutations in MmpL3 alter membrane potential, hydrophobicity and antibiotic susceptibility in Mycobacterium smegmatis. Microbiology 163, 1065\u20131070 (2017).","DOI":"10.1099\/mic.0.000498"},{"key":"37184_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1021\/acsinfecdis.9b00162","volume":"6","author":"AE Grzegorzewicz","year":"2020","unstructured":"Grzegorzewicz, A. E. et al. Mechanisms of resistance associated with the inhibition of the dehydration step of type II fatty acid synthase in Mycobacterium tuberculosis. ACS Infect. Dis. 6, 195\u2013204 (2020).","journal-title":"ACS Infect. Dis."},{"key":"37184_CR34","doi-asserted-by":"publisher","first-page":"38434","DOI":"10.1074\/jbc.M112.400994","volume":"287","author":"AE Grzegorzewicz","year":"2012","unstructured":"Grzegorzewicz, A. E. et al. A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. J Biol. Chem. 287, 38434\u201338441 (2012).","journal-title":"J Biol. Chem."},{"key":"37184_CR35","doi-asserted-by":"crossref","unstructured":"Poulton, N. C., Azadian, Z. A., DeJesus, M. A. & Rock, J. M. Mutations in rv0678 confer low-level resistance to benzothiazinone DprE1 inhibitors in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 66, e0090422 (2022).","DOI":"10.1128\/aac.00904-22"},{"key":"37184_CR36","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1128\/AAC.00308-15","volume":"59","author":"HL Haver","year":"2015","unstructured":"Haver, H. L. et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59, 5316\u20135323 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"37184_CR37","doi-asserted-by":"crossref","unstructured":"Rifat, D. et al. Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 65, e01948-20 (2020).","DOI":"10.1128\/AAC.01948-20"},{"key":"37184_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nmicrobiol.2016.274","volume":"2","author":"JM Rock","year":"2017","unstructured":"Rock, J. M. et al. Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform. Nat. Microbiol. 2, 1\u20139 (2017).","journal-title":"Nat. Microbiol."},{"key":"37184_CR39","doi-asserted-by":"crossref","unstructured":"McNeil, M. & Cook, G. Utilization of CRISPR interference to validate MmpL3 as a drug target in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 63, e00629-19 (2019).","DOI":"10.1128\/AAC.00629-19"},{"key":"37184_CR40","doi-asserted-by":"publisher","first-page":"e69418","DOI":"10.7554\/eLife.69418","volume":"10","author":"S Zhou","year":"2021","unstructured":"Zhou, S. et al. Structure of Mycobacterium tuberculosis cytochrome bcc in complex with Q203 and TB47, two anti-TB drug candidates. Elife 10, e69418 (2021).","journal-title":"Elife"},{"key":"37184_CR41","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/ja.2014.74","volume":"67","author":"P Lu","year":"2014","unstructured":"Lu, P. et al. The ATP synthase inhibitor bedaquiline interferes with small-molecule efflux in Mycobacterium smegmatis. J. Antibiot. 67, 835\u2013837 (2014).","journal-title":"J. Antibiot."},{"key":"37184_CR42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.molcel.2005.02.009","volume":"17","author":"OA Trivedi","year":"2005","unstructured":"Trivedi, O. A. et al. Dissecting the mechanism and assembly of a complex virulence mycobacterial lipid. Mol. Cell 17, 631\u2013643 (2005).","journal-title":"Mol. Cell"},{"key":"37184_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nchembio.1277","volume":"9","author":"R Wilson","year":"2013","unstructured":"Wilson, R. et al. Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. Nat. Chem. Biol. 9, 499\u2013506 (2013).","journal-title":"Nat. Chem. Biol."},{"key":"37184_CR44","doi-asserted-by":"crossref","unstructured":"Li, S. et al. CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis. Nat. Microbiol. 7, 766\u2013779 (2022).","DOI":"10.1038\/s41564-022-01130-y"},{"key":"37184_CR45","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1073\/pnas.1704376114","volume":"114","author":"C Vilch\u00e8ze","year":"2017","unstructured":"Vilch\u00e8ze, C. et al. Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 114, 4495\u20134500 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37184_CR46","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1074\/jbc.RA118.005732","volume":"294","author":"BS Lee","year":"2019","unstructured":"Lee, B. S. et al. Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria. Journal of Biological Chemistry 294, 1936\u20131943 (2019).","journal-title":"Journal of Biological Chemistry"},{"key":"37184_CR47","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1128\/AAC.00395-15","volume":"59","author":"B Lechartier","year":"2015","unstructured":"Lechartier, B. & Cole, S. T. Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59, 4457\u20134463 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"37184_CR48","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","volume":"182","author":"A Van Deun","year":"2010","unstructured":"Van Deun, A. et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182, 684\u2013692 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"37184_CR49","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1164\/rccm.201304-0753OC","volume":"188","author":"JH Grosset","year":"2013","unstructured":"Grosset, J. H. et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am. J. Respir. Crit. Care Med. 188, 608\u2013612 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"37184_CR50","doi-asserted-by":"publisher","first-page":"106509","DOI":"10.1016\/j.ijantimicag.2021.106509","volume":"59","author":"S Kim","year":"2022","unstructured":"Kim, S. et al. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid. Int. J. Antimicrob. Agents 59, 106509 (2022).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"37184_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-12956-2","volume":"10","author":"T Beites","year":"2019","unstructured":"Beites, T. et al. Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nat. Commun. 10, 1\u201312 (2019).","journal-title":"Nat. Commun."},{"key":"37184_CR52","unstructured":"US Food & Drug Administration. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs (2019)."},{"key":"37184_CR53","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.2147\/DDDT.S281639","volume":"15","author":"SL Stancil","year":"2021","unstructured":"Stancil, S. L., Mirzayev, F. & Abdel-Rahman, S. M. Profiling pretomanid as a therapeutic option for TB infection: evidence to date. Drug Des. Dev. Ther. 15, 2815 (2021).","journal-title":"Drug Des. Dev. Ther."},{"key":"37184_CR54","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tube.2017.12.006","volume":"108","author":"M Fujiwara","year":"2018","unstructured":"Fujiwara, M., Kawasaki, M., Hariguchi, N., Liu, Y. & Matsumoto, M. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis 108, 186\u2013194 (2018).","journal-title":"Tuberculosis"},{"key":"37184_CR55","doi-asserted-by":"publisher","first-page":"e02141","DOI":"10.1128\/AAC.02141-18","volume":"63","author":"N Ismail","year":"2019","unstructured":"Ismail, N., Peters, R. P., Ismail, N. A. & Omar, S. V. Clofazimine exposure in vitro selects efflux pump mutants and bedaquiline resistance. Antimicrob. Agents Chemother. 63, e02141\u201302118 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"37184_CR56","doi-asserted-by":"publisher","first-page":"6810","DOI":"10.1128\/AEM.02500-16","volume":"82","author":"T Jirapanjawat","year":"2016","unstructured":"Jirapanjawat, T. et al. The redox cofactor F420 protects mycobacteria from diverse antimicrobial compounds and mediates a reductive detoxification system. Appl. Environ. Microbiol. 82, 6810\u20136818 (2016).","journal-title":"Appl. Environ. Microbiol."},{"key":"37184_CR57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.tube.2008.08.003","volume":"89","author":"A Milano","year":"2009","unstructured":"Milano, A. et al. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5\u2013MmpL5 efflux system. Tuberculosis 89, 84\u201390 (2009).","journal-title":"Tuberculosis"},{"key":"37184_CR58","doi-asserted-by":"publisher","first-page":"e02509","DOI":"10.1128\/AAC.02509-16","volume":"61","author":"I Halloum","year":"2017","unstructured":"Halloum, I. et al. Resistance to thiacetazone derivatives active against Mycobacterium abscessus involves mutations in the MmpL5 transcriptional repressor MAB_4384. Antimicrob. Agents Chemother. 61, e02509\u2013e02516 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"37184_CR59","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/pathogens9030166","volume":"9","author":"DA Maslov","year":"2020","unstructured":"Maslov, D. A., Shur, K. V., Vatlin, A. A. & Danilenko, V. N. MmpS5-MmpL5 transporters provide Mycobacterium smegmatis resistance to imidazo [1, 2-b][1, 2, 4, 5] tetrazines. Pathogens 9, 166 (2020).","journal-title":"Pathogens"},{"key":"37184_CR60","doi-asserted-by":"crossref","unstructured":"Chen, X., Li, Y., Wang, B. & Lu, Y. Identification of mutations associated with Macozinone-resistance in Mycobacterium tuberculosis. Curr. Microbiol. 79, 205 (2022).","DOI":"10.1007\/s00284-022-02881-x"},{"key":"37184_CR61","doi-asserted-by":"publisher","first-page":"fuab050","DOI":"10.1093\/femsre\/fuab050","volume":"46","author":"S Remm","year":"2022","unstructured":"Remm, S., Earp, J. C., Dick, T., Dartois, V. & Seeger, M. A. Critical discussion on drug efflux in Mycobacterium tuberculosis. FEMS Microbiol. Rev. 46, fuab050 (2022).","journal-title":"FEMS Microbiol. Rev."},{"key":"37184_CR62","doi-asserted-by":"publisher","first-page":"e1003008","DOI":"10.1371\/journal.pmed.1003008","volume":"17","author":"AS Dean","year":"2020","unstructured":"Dean, A. S. et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: a multicountry analysis of cross-sectional data. PLoS Med. 17, e1003008 (2020).","journal-title":"PLoS Med."},{"key":"37184_CR63","doi-asserted-by":"publisher","first-page":"20220793","DOI":"10.1098\/rsif.2022.0793","volume":"20","author":"C Nyhoegen","year":"2023","unstructured":"Nyhoegen, C. & Uecker, H. Sequential antibiotic therapy in the laboratory and in the patient. J. R. Soc. Interface 20, 20220793 (2023).","journal-title":"J. R. Soc. Interface"},{"key":"37184_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-25927-3","volume":"12","author":"L Aulin","year":"2021","unstructured":"Aulin, L., Liakopoulos, A., van der Graaf, P. H., Rozen, D. E. & van Hasselt, J. Design principles of collateral sensitivity-based dosing strategies. Nat. Commun. 12, 1\u201314 (2021).","journal-title":"Nat. Commun."},{"key":"37184_CR65","doi-asserted-by":"publisher","first-page":"e01055","DOI":"10.1128\/mSystems.01055-21","volume":"6","author":"RC Allen","year":"2021","unstructured":"Allen, R. C., Pfrunder-Cardozo, K. R. & Hall, A. R. Collateral sensitivity interactions between antibiotics depend on local abiotic conditions. Msystems 6, e01055\u201301021 (2021).","journal-title":"Msystems"},{"key":"37184_CR66","doi-asserted-by":"publisher","first-page":"e1007846","DOI":"10.1371\/journal.ppat.1007846","volume":"15","author":"AF Carey","year":"2019","unstructured":"Carey, A. F. et al. Correction: TnSeq of Mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities. PLoS Pathogens 15, e1007846 (2019).","journal-title":"PLoS Pathogens"},{"key":"37184_CR67","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ng.2656","volume":"45","author":"CB Ford","year":"2013","unstructured":"Ford, C. B. et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat. Genet. 45, 784\u2013790 (2013).","journal-title":"Nat. Genet."},{"key":"37184_CR68","doi-asserted-by":"publisher","first-page":"4579.e4","DOI":"10.1016\/j.cell.2021.06.033","volume":"184","author":"B Bosch","year":"2021","unstructured":"Bosch, B. et al. Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis. Cell 184, 4579.e4\u20134592.e4 (2021).","journal-title":"Cell"},{"key":"37184_CR69","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1365-2958.2012.08099.x","volume":"85","author":"G Brandis","year":"2012","unstructured":"Brandis, G., Wrande, M., Liljas, L. & Hughes, D. Fitness\u2010compensatory mutations in rifampicin\u2010resistant RNA polymerase. Mol. Microbiol. 85, 142\u2013151 (2012).","journal-title":"Mol. Microbiol."},{"key":"37184_CR70","doi-asserted-by":"publisher","first-page":"e2001586","DOI":"10.1371\/journal.pbio.2001586","volume":"15","author":"P Yen","year":"2017","unstructured":"Yen, P. & Papin, J. A. History of antibiotic adaptation influences microbial evolutionary dynamics during subsequent treatment. PLoS Biol. 15, e2001586 (2017).","journal-title":"PLoS Biol."},{"key":"37184_CR71","doi-asserted-by":"publisher","first-page":"121.e4","DOI":"10.1016\/j.cell.2017.12.012","volume":"172","author":"L Imamovic","year":"2018","unstructured":"Imamovic, L. et al. Drug-driven phenotypic convergence supports rational treatment strategies of chronic infections. Cell 172, 121.e4\u2013134.e4 (2018).","journal-title":"Cell"},{"key":"37184_CR72","doi-asserted-by":"crossref","unstructured":"Dean, A. S. et al. 25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward. Lancet Infect. Dis. 22, E191\u2013E196 (2022).","DOI":"10.1016\/S1473-3099(21)00808-2"},{"key":"37184_CR73","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.tim.2016.03.007","volume":"24","author":"V Eldholm","year":"2016","unstructured":"Eldholm, V. & Balloux, F. Antimicrobial resistance in Mycobacterium tuberculosis: the odd one out. Trends Microbiol. 24, 637\u2013648 (2016).","journal-title":"Trends Microbiol."},{"key":"37184_CR74","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/jac\/dkt364","volume":"69","author":"M McGrath","year":"2014","unstructured":"McGrath, M., Gey van Pittius, N., Van Helden, P., Warren, R. & Warner, D. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 69, 292\u2013302 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"37184_CR75","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1021\/acsinfecdis.9b00373","volume":"6","author":"EO Johnson","year":"2019","unstructured":"Johnson, E. O., Office, E., Kawate, T., Orzechowski, M. & Hung, D. T. Large-scale chemical-genetic strategy enables the design of antimicrobial combination chemotherapy in Mycobacteria. ACS Infect. Dis. 6, 56\u201363 (2019).","journal-title":"ACS Infect. Dis."},{"key":"37184_CR76","doi-asserted-by":"publisher","first-page":"e01296","DOI":"10.1128\/AAC.01296-17","volume":"61","author":"MB McNeil","year":"2017","unstructured":"McNeil, M. B., Dennison, D. D., Shelton, C. D. & Parish, T. In vitro isolation and characterization of oxazolidinone-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 61, e01296\u201301217 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"37184_CR77","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3389\/fmicb.2017.00816","volume":"8","author":"LJ Jahn","year":"2017","unstructured":"Jahn, L. J., Munck, C., Ellabaan, M. M. & Sommer, M. O. Adaptive laboratory evolution of antibiotic resistance using different selection regimes lead to similar phenotypes and genotypes. Front. Microbiol. 8, 816 (2017).","journal-title":"Front. Microbiol."},{"key":"37184_CR78","doi-asserted-by":"publisher","unstructured":"McNeil, M., Ryburn, H., Harold, L. K., Tirados, J. & GM., C. Transcriptional inhibition of the F1F0-Type ATP synthase has bactericidal consequences on the viability of Mycobacteria. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac (2020).","DOI":"10.1128\/aac"},{"key":"37184_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-022-03110-8","volume":"5","author":"K Hards","year":"2022","unstructured":"Hards, K. et al. An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis. Commun. Biol. 5, 1\u201311 (2022).","journal-title":"Commun. Biol."},{"key":"37184_CR80","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1046\/j.1365-2672.2000.01017.x","volume":"88","author":"R Lambert","year":"2000","unstructured":"Lambert, R. & Pearson, J. Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non\u2010inhibitory concentration (NIC) values. J. Appl. Microbiol. 88, 784\u2013790 (2000).","journal-title":"J. Appl. Microbiol."},{"key":"37184_CR81","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1126\/science.1124410","volume":"312","author":"S Gagneux","year":"2006","unstructured":"Gagneux, S. et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312, 1944\u20131946 (2006).","journal-title":"Science"},{"key":"37184_CR82","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/jac\/dkab437","volume":"77","author":"C-Y Cheung","year":"2022","unstructured":"Cheung, C.-Y., McNeil, M. B. & Cook, G. M. Utilization of CRISPR interference to investigate the contribution of genes to pathogenesis in a macrophage model of Mycobacterium tuberculosis infection. J. Antimicrob. Chemother. 77, 615\u2013619 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"37184_CR83","unstructured":"Bushnell, B. BBMap. http:\/\/sourceforge.net\/projects\/bbmap\/ (2023)."},{"key":"37184_CR84","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"37184_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2353\/jmoldx.2007.060081","volume":"9","author":"S Ogino","year":"2007","unstructured":"Ogino, S. et al. Standard mutation nomenclature in molecular diagnostics: practical and educational challenges. J. Mol. Diagn. 9, 1\u20136 (2007).","journal-title":"J. Mol. Diagn."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37184-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37184-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37184-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T16:02:27Z","timestamp":1679846547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37184-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,18]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37184"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-37184-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,18]]},"assertion":[{"value":"17 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1517"}}